Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study
중증 COVID-19 폐렴 성인 환자의 치료를 위한 Tocilizumab: 단일 센터 코호트 연구
Article
[키워드] 6-point ordinal scale
95% confidence interval
adjusted odds ratio
adverse events
all-cause mortality
analyzed
Body
body temperature
C-reactive protein
cardiac rate
cardiac rates
clinical
Clinical improvement
clinical status
cohort study
consecutive patient
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 pneumonia
cytokine release
decrease
dose
dropped
Evidence
hospital discharge
hyperinflammatory phase
immunomodulation
immunomodulatory therapy
interferon
intravenous
Laboratory
Lactate
lactate dehydrogenase
lead
lymphocyte
Lymphocyte count
monoclonal antibody
Mortality
Ordinal Scale
outcome
oxygen
oxygen saturation
Patient
Pneumonia
Primary outcome
pulse oximetry
Rate
receptor
respiratory
Safe
SARS-CoV-2
secondary
Secondary outcomes
serum lactate
severe COVID-19
Severe COVID-19 pneumonia
significantly
single-center
single-center study
TCZ
temperature
Tocilizumab
Treatment
vital sign
vital signs
with COVID-19
[DOI] 10.1002/jmv.26308 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/jmv.26308 PMC 바로가기 [Article Type] Article